Zhejiang Jolly Pharmaceutical Co.,LTD (SHE:300181)
China · Delayed Price · Currency is CNY 15.22
+0.01 (0.07%)
May 6, 2026, 3:04 PM CST
SHE:300181 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 3,114 | 3,041 | 2,569 | 1,937 | 1,787 | 1,450 |
Other Revenue | - | - | 8.95 | 5.2 | 18.23 | 7.26 |
| 3,114 | 3,041 | 2,578 | 1,942 | 1,805 | 1,457 | |
Revenue Growth (YoY) | 14.10% | 17.96% | 32.71% | 7.61% | 23.86% | 33.60% |
Cost of Revenue | 1,170 | 1,168 | 1,019 | 616.36 | 534.65 | 420.35 |
Gross Profit | 1,944 | 1,873 | 1,559 | 1,326 | 1,271 | 1,037 |
Selling, General & Admin | 1,140 | 1,090 | 949.08 | 874.18 | 921.45 | 794.25 |
Research & Development | 66.61 | 69.42 | 71.94 | 79.38 | 64.43 | 45.63 |
Other Operating Expenses | -83.82 | -83.72 | -58.7 | -49.99 | -42.32 | -28.31 |
Operating Expenses | 1,123 | 1,076 | 968.57 | 904.42 | 948.8 | 812.78 |
Operating Income | 821.59 | 796.99 | 590.51 | 421.66 | 321.71 | 224.26 |
Interest Expense | - | - | -9.29 | -7.62 | -8.32 | -12.07 |
Interest & Investment Income | - | - | 15.95 | 22 | 4.64 | 4.41 |
Currency Exchange Gain (Loss) | - | - | 0 | 0 | -0 | - |
Other Non Operating Income (Expenses) | -25.11 | -27.84 | -0.47 | 0.18 | -0.01 | -1.13 |
EBT Excluding Unusual Items | 796.48 | 769.15 | 596.7 | 436.21 | 318.02 | 215.47 |
Gain (Loss) on Sale of Investments | -4 | -3.46 | -0.66 | -0.1 | 0.08 | 0.52 |
Gain (Loss) on Sale of Assets | 0.59 | 0.59 | 0.35 | 0.28 | -9.71 | -1.92 |
Asset Writedown | -13.54 | -10.61 | -8.06 | -0.53 | - | - |
Other Unusual Items | - | - | 8.36 | 10.78 | 15.74 | 8.24 |
Pretax Income | 779.54 | 755.67 | 596.69 | 446.64 | 324.12 | 222.31 |
Income Tax Expense | 118.48 | 113.23 | 80.73 | 55.88 | 38.6 | 30.33 |
Earnings From Continuing Operations | 661.06 | 642.44 | 515.96 | 390.76 | 285.52 | 191.98 |
Net Income to Company | 661.06 | 642.44 | 515.96 | 390.76 | 285.52 | 191.98 |
Minority Interest in Earnings | -10.69 | -10.5 | -8.19 | -7.83 | -12.51 | -12.58 |
Net Income | 650.37 | 631.93 | 507.77 | 382.94 | 273.01 | 179.41 |
Net Income to Common | 650.37 | 631.93 | 507.77 | 382.94 | 273.01 | 179.41 |
Net Income Growth | 19.01% | 24.45% | 32.60% | 40.27% | 52.17% | 102.03% |
Shares Outstanding (Basic) | 687 | 687 | 696 | 696 | 607 | 619 |
Shares Outstanding (Diluted) | 694 | 694 | 696 | 696 | 607 | 619 |
Shares Change (YoY) | -0.16% | -0.17% | -0.10% | 14.76% | -1.93% | 1.64% |
EPS (Basic) | 0.95 | 0.92 | 0.73 | 0.55 | 0.45 | 0.29 |
EPS (Diluted) | 0.94 | 0.91 | 0.73 | 0.55 | 0.45 | 0.29 |
EPS Growth | 19.19% | 24.66% | 32.73% | 22.22% | 55.17% | 98.77% |
Free Cash Flow | 355.75 | 124.66 | 34.16 | 156.75 | 140.56 | 103.84 |
Free Cash Flow Per Share | 0.51 | 0.18 | 0.05 | 0.23 | 0.23 | 0.17 |
Dividend Per Share | - | - | 0.600 | 0.450 | 0.300 | 0.200 |
Dividend Growth | - | - | 33.33% | 50.00% | 50.00% | 100.00% |
Gross Margin | 62.43% | 61.60% | 60.48% | 68.27% | 70.38% | 71.16% |
Operating Margin | 26.38% | 26.21% | 22.91% | 21.71% | 17.82% | 15.39% |
Profit Margin | 20.89% | 20.78% | 19.70% | 19.71% | 15.12% | 12.31% |
Free Cash Flow Margin | 11.42% | 4.10% | 1.32% | 8.07% | 7.79% | 7.12% |
EBITDA | 900.36 | 873.44 | 657.69 | 483.23 | 378.43 | 277.87 |
EBITDA Margin | 28.91% | 28.72% | 25.51% | 24.88% | 20.96% | 19.07% |
D&A For EBITDA | 78.77 | 76.45 | 67.18 | 61.58 | 56.72 | 53.61 |
EBIT | 821.59 | 796.99 | 590.51 | 421.66 | 321.71 | 224.26 |
EBIT Margin | 26.38% | 26.21% | 22.91% | 21.71% | 17.82% | 15.39% |
Effective Tax Rate | 15.20% | 14.98% | 13.53% | 12.51% | 11.91% | 13.64% |
Revenue as Reported | - | - | 2,578 | 1,942 | 1,805 | 1,457 |
Advertising Expenses | - | - | 28 | 15.71 | 675.37 | 528.45 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.